Despite positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from pharmacy benefit managers. Such companies are https://lawsonfxrn089796.bloggactivo.com/41057122/company-s-drug-faces-is-meeting-pbm-hurdles-a-look-at-reimbursement-disputes